Page breadcrumb nav

VAERS Report 2156751

Case Report Section

Détails du rapport Vaer

Âge: 44 ans

Genre: Female

Région : Outside US

Patient décédé?
Non
Renseignements sur les vaccins

Nom: COVID19 (COVID19 (PFIZER-BIONTECH))

Type : Coronavirus 2019 vaccine

Fabricant: PFIZER

Lot: fu5254


Date de réception du rapport
2022-03-04
Date à laquelle le formulaire est complèté
Date de vaccination
2022-01-20
Date d’apparition
0
Nombre de jours (date d’apparition – date de vaccination)
0
Description de l’événement indésirable

intermenstrual bleeding; off-label use; interchange of vaccine products; bleeding; had 3 periods within 26 days heavy bleeding with each; this is a spontaneous report received from contactable reporter (consumer or other non hcp) from the regulatory authority-web. regulatory number: gb-mhra-webcovid-202202152027412770-apgja (ra). other case identifier: gb-mhra-adr 26608350 (ra). a 44-year-old female patient (not pregnant) received bnt162b2 (comirnaty), administration date 20jan2022 (lot number: fu5254), at the age of 44 years as dose 2 (initial pfizer dose), single for covid-19 immunization. relevant medical history included: "immunodeficiency" (unknown if ongoing), notes: taking other treatments or medicines, not listed above, known to lower the immune response; "hidradenitis" (unknown if ongoing) and "suspected covid-19" (ongoing), notes: unsure when symptoms started. the patient last menstrual period (lmp) date on 14feb2022. the patient's concomitant medications were not reported. past drug history included: humira for hidradenitis. vaccination history included: covid-19 vaccine astrazeneca (dose 1, single), administration date: 17feb2021 for covid-19 immunization. patient was not breast feeding at the time of report. patient had not tested positive for covid-19 since having the vaccine. patient was not enrolled in a clinical trial. the following information was reported: off label use (medically significant) with onset 20jan2022, outcome "unknown", described as "off-label use"; interchange of vaccine products (medically significant) with onset 20jan2022, outcome "unknown", described as "interchange of vaccine products"; intermenstrual bleeding (medically significant) with onset 24jan2022, outcome "not recovered", described as "intermenstrual bleeding"; haemorrhage (medically significant) with onset 2022, outcome "not recovered", described as "bleeding" and heavy menstrual bleeding (non-serious) with onset 2022, outcome "unknown", described as "had 3 periods within 26 days heavy bleeding with each". the patient underwent the following laboratory tests and procedures: sars-cov-2 test: (04oct2021) positive, notes: yes - positive covid-19 test. this report doesn't relate to possible inflammation of the heart (myocarditis or pericarditis). no follow-up attempts are possible. no further information is expected

Données de laboratoire
test date: 20211004; test name: covid-19 virus test; test result: positive ; comments: yes - positive covid-19 test
Liste des symptômes
heavy menstrual bleeding haemorrhage interchange of vaccine products sars-cov-2 test off label use intermenstrual bleeding
Patient décédé?
Non
Date de décès
N/A
Anomalie congénitale
false
Vaccin administré par :
Other
Vaccin acheté par :
Inconnu
Visite d’un patient à l’urgence?
Non
Patient hospitalisé?
Non
Séjour à l’hôpital
Non
Nombre de jours à l’hôpital
Non spécifié
Invalidité permanente?
Non
Allergies:
na
Maladie actuelle
suspected covid-19 (unsure when symptoms started)